Literature DB >> 21698647

Reliability of the Modified Hammersmith Functional Motor Scale in young children with spinal muscular atrophy.

Kristin J Krosschell1, Charles B Scott, Jo Anne Maczulski, Aga J Lewelt, Sandra P Reyna, Kathryn J Swoboda.   

Abstract

INTRODUCTION: The test-retest reliability of the Modified Hammersmith Functional Motor Scale (MHFMS) in children with spinal muscular atrophy (SMA) ≤30 months of age was assessed. The age at which typically developing children (TD) achieve maximum MHFMS scores was also studied.
METHODS: Twenty-two children with SMA type II [mean age (SD) = 20 (5) months, range 9-30 months) were tested twice using the MHFMS. Twenty-five TD children [mean age (SD) = 18 (7) months, range 9-30 months) were tested once.
RESULTS: The average difference between MHFMS scores for SMA children was 0.18 [first assessment: mean (SD) = 12.8 (9.8); second assessment: mean (SD) = 13.0 (8.8)]. Reliability was excellent (ICC(1,3) = 0.96, SEM 1.86). TD participants had MHFMS scores ranging from 36 to 40 [mean (SD) = 39.2 (1.2)] and achieved maximum test scores at 12 months of age. DISCUSSION: MHFMS scores in young children with SMA type II showed excellent test-retest stability. This suggests that the MHFMS can be used reliably in this younger population for clinical trials and follow-up.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21698647      PMCID: PMC3136587          DOI: 10.1002/mus.22040

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  33 in total

1.  The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation.

Authors:  Marion Main; Harvey Kairon; Eugenio Mercuri; Francesco Muntoni
Journal:  Eur J Paediatr Neurol       Date:  2003       Impact factor: 3.140

2.  Choosing the right clinical outcome measure: from the patient to the statistician and back.

Authors:  Eugenio Mercuri; Elena Mazzone
Journal:  Neuromuscul Disord       Date:  2010-09-28       Impact factor: 4.296

3.  Effect of maternal education and ethnic background on infant development.

Authors:  T Ivanans
Journal:  Arch Dis Child       Date:  1975-06       Impact factor: 3.791

4.  The predictive value of achieved motor milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III.

Authors:  S Rudnik-Schöneborn; I Hausmanowa-Petrusewicz; J Borkowska; K Zerres
Journal:  Eur Neurol       Date:  2001       Impact factor: 1.710

Review 5.  An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA).

Authors:  B Wirth
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

Review 6.  Concerns about the design of clinical trials for spinal muscular atrophy.

Authors:  Thomas O Crawford
Journal:  Neuromuscul Disord       Date:  2004-09       Impact factor: 4.296

7.  Pilot trial of phenylbutyrate in spinal muscular atrophy.

Authors:  Eugenio Mercuri; Enrico Bertini; Sonia Messina; Marco Pelliccioni; Adele D'Amico; Francesca Colitto; Massimiliano Mirabella; Francesco D Tiziano; Tiziana Vitali; Carla Angelozzi; Maria Kinali; Marion Main; Christina Brahe
Journal:  Neuromuscul Disord       Date:  2004-02       Impact factor: 4.296

8.  Rolling over in infants: age, ethnicity, and cultural differences.

Authors:  E A S Nelson; L M Yu; D Wong; H Y E Wong; L Yim
Journal:  Dev Med Child Neurol       Date:  2004-10       Impact factor: 5.449

Review 9.  Racial/ethnic variation in the motor development and performance of American children.

Authors:  R M Malina
Journal:  Can J Sport Sci       Date:  1988-06

10.  Reliability of 4 outcome measures in pediatric spinal muscular atrophy.

Authors:  Susan T Iannaccone; Linda S Hynan
Journal:  Arch Neurol       Date:  2003-08
View more
  10 in total

1.  Rasch analysis of clinical outcome measures in spinal muscular atrophy.

Authors:  Stefan J Cano; Anna Mayhew; Allan M Glanzman; Kristin J Krosschell; Kathryn J Swoboda; Marion Main; Birgit F Steffensen; Carole Bérard; Françoise Girardot; Christine A M Payan; Eugenio Mercuri; Elena Mazzone; Bakri Elsheikh; Julaine Florence; Linda S Hynan; Susan T Iannaccone; Leslie L Nelson; Shree Pandya; Michael Rose; Charles Scott; Reza Sadjadi; Mackensie A Yore; Cynthia Joyce; John T Kissel
Journal:  Muscle Nerve       Date:  2013-07-26       Impact factor: 3.217

Review 2.  New therapeutic approaches to spinal muscular atrophy.

Authors:  Aga Lewelt; Tara M Newcomb; Kathryn J Swoboda
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

3.  Reliability and validity of the TIMPSI for infants with spinal muscular atrophy type I.

Authors:  Kristin J Krosschell; Jo Anne Maczulski; Charles Scott; Wendy King; Jill T Hartman; Laura E Case; Donata Viazzo-Trussell; Janine Wood; Carolyn A Roman; Eva Hecker; Marianne Meffert; Maude Léveillé; Krista Kienitz; Kathryn J Swoboda
Journal:  Pediatr Phys Ther       Date:  2013       Impact factor: 3.049

4.  Efficacy and Safety of Valproic Acid for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis.

Authors:  Abdelrahman Elshafay; Truong Hong Hieu; Mohamed Fahmy Doheim; Mahmoud Attia Mohamed Kassem; Mohammed Fathi ELdoadoa; Sarah Keturah Holloway; Heba Abo-Elghar; Kenji Hirayama; Nguyen Tien Huy
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

5.  The motor neuron response to SMN1 deficiency in spinal muscular atrophy.

Authors:  Peter B Kang; Clifton L Gooch; Michael P McDermott; Basil T Darras; Richard S Finkel; Michele L Yang; Douglas M Sproule; Wendy K Chung; Petra Kaufmann; Darryl C de Vivo
Journal:  Muscle Nerve       Date:  2014-05       Impact factor: 3.217

6.  Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study.

Authors:  Kristin J Krosschell; Michael Bosch; Leslie Nelson; Tina Duong; Linda P Lowes; Lindsay N Alfano; Danielle Benjamin; Terri B Carry; Ginger Devine; Carolyn Kelley; Rebecca Gadekan; Elizabeth C Malkus; Amy Pasternak; Stephanie Provance-Orr; Lynne Roemeiser-Logan; Alina Nicorici; Donata Trussell; Sally Dunaway Young; Jennifer R Fetterman; Jacqueline Montes; Penny J Powers; Rebecca Quinones; Janet Quigley; Christopher S Coffey; Jon W Yankey; Amy Bartlett; John T Kissel; Stephen J Kolb
Journal:  J Neuromuscul Dis       Date:  2018

7.  Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool.

Authors:  Danielle Ramsey; Mariacristina Scoto; Anna Mayhew; Marion Main; Elena S Mazzone; Jacqueline Montes; Roberto de Sanctis; Sally Dunaway Young; Rachel Salazar; Allan M Glanzman; Amy Pasternak; Janet Quigley; Elizabeth Mirek; Tina Duong; Richard Gee; Matthew Civitello; Gihan Tennekoon; Marika Pane; Maria Carmela Pera; Kate Bushby; John Day; Basil T Darras; Darryl De Vivo; Richard Finkel; Eugenio Mercuri; Francesco Muntoni
Journal:  PLoS One       Date:  2017-02-21       Impact factor: 3.240

8.  Gross Motor Function Disorders in Patients with Alternating Hemiplegia of Childhood.

Authors:  Agnieszka Stępień; Katarzyna Maślanko; Maciej Krawczyk; Witold Rekowski; Anna Kostera-Pruszczyk
Journal:  J Mother Child       Date:  2020-07-29

9.  Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network.

Authors:  Anne M Connolly; Julaine M Florence; Mary M Cradock; Elizabeth C Malkus; Jeanine R Schierbecker; Catherine A Siener; Charlie O Wulf; Pallavi Anand; Paul T Golumbek; Craig M Zaidman; J Philip Miller; Linda P Lowes; Lindsay N Alfano; Laurence Viollet-Callendret; Kevin M Flanigan; Jerry R Mendell; Craig M McDonald; Erica Goude; Linda Johnson; Alina Nicorici; Peter I Karachunski; John W Day; Joline C Dalton; Janey M Farber; Karen K Buser; Basil T Darras; Peter B Kang; Susan O Riley; Elizabeth Shriber; Rebecca Parad; Kate Bushby; Michelle Eagle
Journal:  Neuromuscul Disord       Date:  2013-05-28       Impact factor: 4.296

10.  Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials.

Authors:  Eugenio Mercuri; Richard Finkel; Jacqueline Montes; Elena S Mazzone; Maria Pia Sormani; Marion Main; Danielle Ramsey; Anna Mayhew; Allan M Glanzman; Sally Dunaway; Rachel Salazar; Amy Pasternak; Janet Quigley; Marika Pane; Maria Carmela Pera; Mariacristina Scoto; Sonia Messina; Maria Sframeli; Gian Luca Vita; Adele D'Amico; Marleen van den Hauwe; Serena Sivo; Nathalie Goemans; Petra Kaufmann; Basil T Darras; Enrico Bertini; Francesco Muntoni; Darryl C De Vivo
Journal:  Neuromuscul Disord       Date:  2015-12-03       Impact factor: 4.296

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.